Article Text

Download PDFPDF
Bridging the gap: understanding sex differences in low-density lipoprotein cholesterol control through the lens of integrated data analysis and behavioural sciences
  1. M Julia Machline-Carrion
  1. Medical Affairs, epHealth, London, UK
  1. Correspondence to Dr M Julia Machline-Carrion, Medical Affairs, epHealth, London, UK; mjuliacarrion{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Low-density lipoprotein cholesterol (LDL-C) is a well-known risk factor for cardiovascular disease, a leading cause of morbidity and mortality worldwide. Traditionally, guidelines for LDL-C management have been largely uniform across genders, with little consideration given to potential sex-based differences in response to treatment. In the realm of healthcare, understanding the intricacies of disease management is paramount to providing effective care. By analysing real-world data (RWD) from a representative population, the study by Kiss et al1 sheds light on sex differences in the prescription of high-intensity statins and achievement of LDL-C target levels within primary care populations and contributes towards personalised and equitable healthcare.

As integrated data analysis emerges as a powerful tool in this endeavour, this study using healthcare records from a population-based network of electronic healthcare data banks that combines data from different primary and secondary healthcare settings in the Netherlands (the PHARMO Data Network)2 offers insights into population-level trends and disparities in healthcare delivery. By aggregating data from various sources such as electronic health records and pharmacy records, healthcare providers gain a comprehensive view …

View Full Text

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MJM-C received research grants from Novartis, Ipsen, GSK and Amgen.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles